CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

NSCLC 围术期治疗：BMS 公布CheckMate-77T 临床结果

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

Ongoing phase 3 neoadjuvant chemoimmunotherapy trials in

News from ESMO - Lung Cancer Research Foundation

ESMO - European Society for Medical Oncology on LinkedIn: New data

AACR: Bristol Myers details Opdivo's presurgery lung cancer win

LUNG CANCER

News from ESMO - Lung Cancer Research Foundation

切除可能なステージIIA-IIIB非小細胞肺がんに対する術前ニボルマブ＋

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

CheckMate-77T: Perioperative nivolumab benefit for NSCLC - ecancer